Q-omics provides the consensus-scored MMADHCP2 profile across patient tissues and cancer cell-line models. MMADHCP2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, MMADHCP2 is differentially expressed in 8, with the highest sampling consensus in COAD. Additionally, MMADHCP2 RNA expression shows 8,972 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight COAD, and ESCA as cancer lineages where MMADHCP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MMADHCP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MMADHCP2 survival associations across molecular data types. MMADHCP2 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MMADHCP2 RNA expression–survival associations across cancer types. High MMADHCP2 expression shows unfavorable associations in COAD, CESC, PAAD, BRCA, LUAD and ACC. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for MMADHCP2 RNA expression.
This table summarizes MMADHCP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for MMADHCP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MMADHCP2 shows lower tumor expression in KICH and higher tumor expression in COAD, LUAD, HNSC, READ and BRCA. The COAD box plot shows higher MMADHCP2 RNA expression in tumor versus normal tissue (log2 FC = +0.194, t-test p = .002).
This table shows molecular features associated with MMADHCP2 in patient tissues and cancer cell lines. In patient samples, MMADHCP2 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
